Blinatumomab Drug Asset Due Diligence Report 2026

This Blinatumomab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

191

Registered trials

307

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Blinatumomab can convert its Bispecific T-cell Engager (BiTE) profile and CD19 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Blinatumomab (query alias: blinatumomab)
Modality / target	Bispecific T-cell Engager (BiTE); CD19 x CD3; CD19 inhibitors, CD3 stimulants
Highest global status	Approved
Originator	Amgen, Inc.
Active developers	Amgen, Inc., National Cancer Institute, Amgen Australia Pty Ltd.

The MCP disease footprint includes Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07686042	Phase 4	Not yet recruiting	12	Proportion of participants with mRS score 0-2
ChiCTR2600127018	Phase 4	Not yet recruiting	12	Modified Rankin Scale, mRS
ChiCTR2600127006	Phase 2	Not yet recruiting	26	MRD negative conversion rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

“IMMUNE DIMMING” WITH LOW-DOSE BLINATUMOMAB REVERSES THE TREATMENT-RESISTANT STATE IN RHEUMATOID ARTHRITIS

Not Applicable; n=15; evaluation: Positive. Reported fields: ACR20 = 100.0 %

A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 2; n=19; evaluation: not stated. Reported fields: Rate of Complete Remission (CR). = 9 Participants ; -; -

The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.

Phase 2; n=27; evaluation: Positive. Reported fields: EFS(2-year) = 79.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Blinatumomab addresses Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-03-02	NCI to establish CRADA with Amgen to assess efficacy of blinatumomab in phase III cancer trial.	Phase 3	Financial terms not disclosed
2019-10-31	Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China	Approved	Financial terms not disclosed
2013-05-29	Amgen And Astellas Announce Japan Alliance	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods comprising oncolytic viruses expressing CD19t and bispecific t cell engagers”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, and infection
Durability after deep B-cell or plasma-cell depletion
Dose-step-up logistics, manufacturing, and outpatient feasibility

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO